Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05539209 · ClinicalTrials.gov registry record · NA
Testing a Novel Smartphone Application for Smoking Cessation With the Oklahoma Helpline
A NA study, sponsored by University of Oklahoma.
- Completed
- Registry status
- NA
- Development phase
- 512
- Enrollment target
NCT05539209: Completed NA study, sponsored by University of Oklahoma.
NCT05539209 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 512 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05539209, a NA study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- NA
- Development phase
- 512 participants
- Enrollment target
Study Summary
Over 470,000 tobacco users have been served by the Oklahoma Tobacco Helpline (OTH). The OTH reaches a substantial number of smokers each year, but follow-up rates are notoriously low and many smokers may prefer smartphone-based smoking cessation interventions rather than web- or phone-based OTH programming (e.g., counseling). Highly flexible and low burden technology-based treatment approaches may overcome barriers that have limited the use and effectiveness of traditional smoking cessation treatments among underserved adult smokers (e.g., racial/ethnic minorities, rural residence, low socioeconomic status). This study is a randomized controlled trial that will evaluate the feasibility and initial efficacy of an innovative, evidence-based smoking cessation app tailored for smokers that contact the OTH for services. A total of 500 treatment-seeking men and women will be randomly assigned to receive either Standard Helpline Care plus brief (30 second) daily check-ins and weekly smartphone-based surveys through the Insight app (SC) or SC plus the OKquit smoking cessation app (OKq). All participants will receive standard Helpline services (e.g., nicotine replacement therapy), but only the OKq group will receive on-demand content and tailored messages through the app. All participants will be followed for 27 weeks after they are randomized to an intervention group and complete smartphone-based survey assessments. Participants that report smoking abstinence during the 26-week EMA will be sent a low-cost carbon monoxide monitor to verify smoking status.
Primary Outcome
Biochemically verified smoking abstinence will be assessed using a portable carbon monoxide monitor.
Interventions
- BEHAVIORAL OKquit
- BEHAVIORAL Standard Helpline Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2025-09-29 |
| Phase | NA |
What the finished NCT05539209 record still lists
NCT05539209 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which OKquit is the first listed.
NCT05539209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05539209 about?
NCT05539209 is a clinical study titled "Testing a Novel Smartphone Application for Smoking Cessation With the Oklahoma Helpline". Over 470,000 tobacco users have been served by the Oklahoma Tobacco Helpline (OTH). The OTH reaches a substantial number of smokers each year, but follow-up rates are notoriously low and many smokers may prefer smartphone-based smoking cessation interventions rather than web- or phone-based OTH prog...
What is the current status of trial NCT05539209?
This trial is currently completed. It is a NA study. The enrollment target is 512 participants. The study started on 2022-09-13. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT05539209?
The interventions under investigation include: OKquit (BEHAVIORAL), Standard Helpline Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT05539209?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05539209's enrollment target sits among peer trials
512 192nd of 2000 higher than 1,809 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI